Search clinical trials for: MK-1942

Total 1801 results

University of Miami
Merck Sharp & Dohme LLC

Terminated

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Cervical Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Eli Lilly and Company; Merck Sharp & Dohme LLC

Completed

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Pancreatic Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Organon and Co

Completed

Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis

Osteoarthritis of the Knee
Organon and Co

Completed

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

Rhinitis, Allergic, Seasonal
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Completed

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism (ACTICAS)

Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment

France
Merck Sharp & Dohme LLC

Completed

Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)

Relapsed or Refractory Multiple Myeloma
Washington University School of Medicine
Merck Sharp & Dohme LLC

Completed

MK-3475 Immunotherapy in Endometrial Carcinoma

Endometrial Cancer | Endometrial Carcinoma | Neoplasms, Endometrial

United States
Merck Sharp & Dohme LLC

Completed

Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

Neoplasms
Merck Sharp & Dohme LLC

Terminated

A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105) (PAPAL)

Fungal Infection
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Sarcoma | Cancer
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Dwight Owen
National Cancer Institute (NCI)

Suspended

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Thymic Carcinoma

United States
Columbia University
National Cancer Institute (NCI); Massachusetts General Hospital; Merck Sharp...

Terminated

Genetic Predictors of Benefit to Pembrolizumab

Carcinoma, Non-Small-Cell Lung

United States
ETOP IBCSG Partners Foundation
Merck Sharp & Dohme LLC; Frontier Science Foundation, Hellas

Completed

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (PROMISE-meso)

Pleural Mesothelioma Malignant Advanced

United Kingdom, Switzerland, Spain
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

Malignant Melanoma
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Type 2 Diabetes Mellitus
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Lung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer AJCC v8

United States
Organon and Co

Completed

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

Spondylarthropathies; Spondylitis, Ankylosing
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Metastatic Colorectal Cancer
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed Carcinoma

United States, Guam, Puerto Rico
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Stomach Neoplasms

China, Japan, Poland, Turkey, Brazil, United States, Argentina, Australia, Canada, Chile, Colombia, Costa Rica, Czechia, Denmark, France, Germany, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, New Zealand and more
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

Gastric Adenocarcinoma | Gastric Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Stomach | Stage IV Esophageal Adenocarcinoma AJCC v7 | Stage IV Esophageal Squamous Cell Carcinoma AJCC v7

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Triple Negative Breast Cancer (TNBC)
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) (DRIVE-AHEAD)

Human Immunodeficiency Virus (HIV)
Merck Sharp & Dohme LLC

Completed

Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

Chronic Hepatitis C
Organon and Co

Completed

Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)

Asthma
Merck Sharp & Dohme LLC

Terminated

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)

Rheumatoid Arthritis
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)

Rheumatoid Arthritis (RA)
Merck Sharp & Dohme LLC

Completed

Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Withdrawn

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

Osteoporosis | Postmenopausal Osteoporosis
Merck Sharp & Dohme LLC

Withdrawn

Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)

Low Back Pain
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Solid Tumor
Shahid Beheshti University of Medical Sciences

Unknown

Topical Diclofenac on Macular Thickness After Phacoemulsification (diclofenac)

Diabetic Oculopathy

Iran, Islamic Republic of
Maastricht University Medical Center

Completed

Arabic Gum-Absorption Study

Bioavailability

Netherlands
Boston University
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Not yet recruiting

The Role of Vitamin K on Knee Osteoarthritis Outcomes

Osteo Arthritis Knee

United States
Mayo Clinic
Merck Sharp & Dohme LLC; NeoImmune Tech

Recruiting

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype | Recurrent Gliosarcoma | High Grade Astrocytic Tumor

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Tianhong Li
National Cancer Institute (NCI); LabyRx Immunologic Therapeutics

Recruiting

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Adenocarcinoma | Advanced Adenocarcinoma | Recurrent Adenocarcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network for Gynaecological Oncological...

Active, not recruiting

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Endometrial Neoplasms

United States, Argentina, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Norway, Poland, Russian Federation, Spain, Sweden, Taiwan, T... and more
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Poorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditions

United States
Axel Diederichsen

Completed

The Aortic Valve DECalcification (AVADEC) Trial (AVADEC)

Aortic Valve Stenosis | Multidetector Computed Tomography | Vitamin K 2 | Randomised Clinical Trial

Denmark
Organon and Co

Completed

Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)

Rhinitis, Allergic

Search clinical trials for: MK-1942

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations